Macrogenics (MGNX) Long-Term Investments (2016 - 2026)
Macrogenics (MGNX) posted quarterly Long-Term Investments of $87.7 million for Q1 2026, up 923.36% year-over-year from $8.6 million in Q1 2025, and down 33.9% quarter-over-quarter from $132.7 million in Q4 2025.
Macrogenics (MGNX) Long-Term Investments (2016 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Long-Term Investments for 11 consecutive years, with $87.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments rose 923.36% year-over-year to $87.7 million; the TTM figure through Mar 2026 stood at $87.7 million (up 923.36% YoY), while the FY2025 annual figure was $132.7 million, up 605.83% from the prior year.
- Long-Term Investments retreated to $87.7 million in Q1 2026 per MGNX's latest filing, from $132.7 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $166.5 million in Q3 2023 and bottomed at $8.6 million in Q1 2025.
- Historically, Long-Term Investments has averaged $77.6 million across 5 years, with a median of $66.3 million in 2025.
- Annual changes were most pronounced in 2025 — Long-Term Investments slumped 91.75% — and 2026, when it jumped 923.36%.
- Macrogenics' Long-Term Investments stood at $45.5 million in 2022, then jumped by 183.18% to $128.8 million in 2023, then plunged by 85.41% to $18.8 million in 2024, then jumped by 605.83% to $132.7 million in 2025, then plunged by 33.9% to $87.7 million in 2026.
- Business Quant data shows MGNX's Long-Term Investments at $87.7 million in Q1 2026, $132.7 million in Q4 2025, and $66.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 87.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.71 Mn |
| Dec 31, 2025 | 132.70 Mn |
| Sep 30, 2025 | 66.27 Mn |
| Jun 30, 2025 | 45.80 Mn |
| Mar 31, 2025 | 8.57 Mn |
| Dec 31, 2024 | 18.80 Mn |
| Sep 30, 2024 | 20.74 Mn |
| Jun 30, 2024 | 56.44 Mn |
| Mar 31, 2024 | 103.88 Mn |
| Dec 31, 2023 | 128.85 Mn |
| Sep 30, 2023 | 166.53 Mn |
| Jun 30, 2023 | 131.59 Mn |
| Mar 31, 2023 | 17.39 Mn |
| Dec 31, 2022 | 45.50 Mn |
| Sep 30, 2022 | 39.62 Mn |
| Jun 30, 2022 | 112.27 Mn |
| Mar 31, 2022 | 136.66 Mn |
| Dec 31, 2021 | 120.10 Mn |
| Sep 30, 2021 | 108.37 Mn |
| Jun 30, 2021 | 108.35 Mn |